Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching


Autoři: Shibin Du aff001;  Jian-Zhi Yang aff002;  Jing Chen aff003;  Wei-gang Zhou aff002;  Yan-Yan Sun aff001
Působiště autorů: Department of Anesthesiology, Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen University General Hospital, Shenzhen, China aff001;  Department of Anesthesiology, Hanzhong Central Hospital, Hanzhong, Shanxi, China aff002;  Department of Endocrinology, The Second Affiliated Hospital, Kunming Medical University, Kunming, Yunnan, China aff003
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227242

Souhrn

Both microwave (MW) ablation and radiofrequency (RF) ablation are widely used for hepatocellular carcinoma (HCC) treatments in clinic. However, it is still unclear if ablative methods could influence the recurrence-free survival (RFS) and overall survival (OS) of HCC patients. Therefore, we carried out this multi-center retrospective cohort study to investigate the differences of recurrence-free survival (RFS) and overall survival (OS) between MW ablation and RF ablation by survival analysis. From January 2014 to December 2016, patients who received thermal ablation surgery for HCC treatment were screened. Finally, 452 patients met the eligibility criteria and finished the follow-up. Univariable and multivariable regression analyses were used to identify independent predictive factors of the RFS and OS. Also, propensity score matching (PSM) was used to balance the bias between two groups. Finally, we found that before the PSM, the univariable and multivariable regression analyses revealed that there were no significant differences on the RFS between two groups. Same results were obtained for the OS. After PSM, 115 pairs of patients were created, and both the univariable and multivariable regression analyses suggested that there were still no significant differences on the RFS between two groups. Same results were obtained for the OS. In conclusion, our present study showed that there were no significant differences between MW ablation and RF ablation for HCC patients on the RFS or OS.

Klíčová slova:

Death rates – Hepatocellular carcinoma – Hypertension – Chemoradiotherapy – Regression analysis – Surgical and invasive medical procedures – Surgical oncology – Surgical resection


Zdroje

1. Allemani C, Matsuda T, Di CV, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023–1075. doi: 10.1016/S0140-6736(17)33326-3 29395269

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30. doi: 10.3322/caac.21442 29313949

3. Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69(3): 718–735. doi: 10.1016/j.jhep.2018.05.011 29777749

4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2): 115–132. doi: 10.3322/caac.21338 26808342

5. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017; 67(2): 302–309. doi: 10.1016/j.jhep.2017.03.011 28336466

6. Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M, et al. The global decrease in cancer mortality: trends and disparities. Ann Oncol. 2016; 27(5): 926–933. doi: 10.1093/annonc/mdw027 26802157

7. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014; 60(6): 2099–2108. doi: 10.1002/hep.27406 25164003

8. Sangiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, et al. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Liver Int. 2018; 38(9): 1624–1634. doi: 10.1111/liv.13888 29791968

9. Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2018; 68(4): 783–797. doi: 10.1016/j.jhep.2017.10.004 29031662

10. Vogl TJ, Farshid P, Naguib NN, Zangos S, Bodelle B, Paul J, et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. Abdom Imaging. 2015; 40(6): 1829–1837. doi: 10.1007/s00261-015-0355-6 25601438

11. Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc. 2014; 28(12): 3429–3434. doi: 10.1007/s00464-014-3617-4 24935203

12. Huo YR, Eslick GD. Microwave Ablation Compared to Radiofrequency Ablation for Hepatic Lesions: A Meta-Analysis. J Vasc Interv Radiol. 2015; 26(8): 1139–1146.e2. doi: 10.1016/j.jvir.2015.04.004 26027937

13. Potretzke TA, Ziemlewicz TJ, Hinshaw JL, Lubner MG, Wells SA, Brace CL, et al. Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center. J Vasc Interv Radiol. 2016; 27(5): 631–638. doi: 10.1016/j.jvir.2016.01.136 27017124

14. Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, et al. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Hepatol. 2009; 24(2): 223–227. doi: 10.1111/j.1440-1746.2008.05596.x 18823439

15. Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One. 2013; 8(10): e76119. doi: 10.1371/journal.pone.0076119 24146824

16. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4): 908–943. doi: 10.1016/j.jhep.2011.12.001 22424438

17. Baek S, Park SH, Won E, Park YR, Kim HJ. Propensity score matching: a conceptual review for radiology researchers. Korean J Radiol. 2015; 16(2): 286–296. doi: 10.3348/kjr.2015.16.2.286 25741190

18. Yang T, Lu JH, Lau WY, Zhang TY, Zhang H, Shen YN, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis. J Hepatol. 2016; 64(3): 583–593. doi: 10.1016/j.jhep.2015.10.012 26596543

19. Boffa DJ, Kosinski AS, Furnary AP, Kim S, Onaitis MW, Tong BC, et al. Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy. J Clin Oncol. 2018; 36(23): 2378–2385. doi: 10.1200/JCO.2018.77.8977 29791289

20. Dong W, Zhang T, Wang ZG, Liu H. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis. World J Gastroenterol. 2014; 20(29): 10174–10182. doi: 10.3748/wjg.v20.i29.10174 25110446

21. Kaibori M, Matsui Y, Hijikawa T, Uchida Y, Kwon AH, Kamiyama Y. Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis C. Surgery. 2006; 139(3): 385–394. doi: 10.1016/j.surg.2005.08.035 16546504

22. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012; 57(4): 794–802. doi: 10.1016/j.jhep.2012.05.007 22634125

23. Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010; 116(15): 3638–3644. doi: 10.1002/cncr.25142 20564097

24. Lee KF, Wong J, Hui JW, Cheung YS, Chong CC, Fong AK, et al. Long-term outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma by surgical approach: A retrospective comparative study. Asian J Surg. 2017; 40(4): 301–308. doi: 10.1016/j.asjsur.2016.01.001 26922631

25. Correa-Gallego C, Fong Y, Gonen M, D'Angelica MI, Allen PJ, DeMatteo RP, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014; 21(13): 4278–4283. doi: 10.1245/s10434-014-3817-0 24889486

26. Carrafiello G, Laganà D, Mangini M, Fontana F, Dionigi G, Boni L, et al. Microwave tumors ablation: principles, clinical applications and review of preliminary experiences. Int J Surg. 2008; 6 Suppl 1: S65–69.

27. Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol. 2008; 19(7): 1087–1092. doi: 10.1016/j.jvir.2008.03.023 18589324

28. Ding J, Jing X, Liu J, Wang Y, Wang F, Wang Y, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol. 2013; 82(9): 1379–1384. doi: 10.1016/j.ejrad.2013.04.025 23726122

29. Sakaguchi H, Seki S, Tsuji K, Teramoto K, Suzuki M, Kioka K, et al. Endoscopic thermal ablation therapies for hepatocellular carcinoma: a multi-center study. Hepatol Res. 2009; 39(1): 47–52. doi: 10.1111/j.1872-034X.2008.00410.x 18761680

30. Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W. Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth. 2011; 106(6): 814–822. doi: 10.1093/bja/aer055 21436156

31. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008; 109(2): 180–187. doi: 10.1097/ALN.0b013e31817f5b73 18648226


Článek vyšel v časopise

PLOS One


2020 Číslo 1